Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia

Affiliations

• ¹ IMPACT Strategic Research Centre, Deakin University, Geelong, Australia; Florey Institute for Neuroscience and Mental Health, Parkville, Australia; Department of Psychiatry, University of Melbourne, Parkville, Australia; Barwon Health, Geelong, Australia. Electronic address: oliviad@barwonhealth.org.au.
• ² Department of Psychiatry, University of Melbourne, Parkville, Australia; St Vincent's Hospital, Melbourne, Australia.
• ³ Florey Institute for Neuroscience and Mental Health, Parkville, Australia; Cooperative Research Centre for Mental Health, Melbourne, Australia.
• ⁴ Florey Institute for Neuroscience and Mental Health, Parkville, Australia; Department of Psychiatry, University of Melbourne, Parkville, Australia; Discipline of Psychiatry, Monash University, Melbourne, Australia.
• ⁵ Department of Psychiatry, Center for Psychiatric Neuroscience, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
• ⁶ Department of Psychiatry, Service of General Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
• ⁷ Brain and Psychological Science Research Centre, Swinburne University of Technology, Hawthorn, Australia; School of Psychiatry and Neurosciences, University of Western Australia, Perth, Australia.
• ⁸ Brain and Psychological Science Research Centre, Swinburne University of Technology, Hawthorn, Australia; School of Psychiatry and Neurosciences, University of Western Australia, Perth, Australia; Department of Psychiatry, University of Capetown, Capetown, South Africa; Faculty of Health Science, Australian Catholic University, Queensland, Australia.
• ⁹ IMPACT Strategic Research Centre, Deakin University, Geelong, Australia; Florey Institute for Neuroscience and Mental Health, Parkville, Australia; Department of Psychiatry, University of Melbourne, Parkville, Australia; Barwon Health, Geelong, Australia; Orygen Research Centre, Parkville, Australia.